TNFSF10 and breast carcinoma: PTHrP is normally expressed in the majority of breast cancers, especially in the late stage metastatic breast cancers, and as such, the expression of PTHrP by cancers may be influential in determining the effectiveness of Apo2L/TRAIL-based therapies in a clinical setting.